Hemostasis Tissue Sealing Agents Market Share

Global Hemostasis and Tissue Sealing Agents Market Overview

Hemostasis and Tissue-Sealing Agents Market Size was prized at USD 3.5 Billion in 2022. The hemostasis and tissue-sealing agents market industry is anticipated to grow from USD 3.78 Billion in 2023 to USD 7.05 Billion by 2032, displaying an annual compound growth rate of 8.10% for the predicted period (2023-2032).The increase in the use of hemostat products for the prevention of blood loss in various general as well as less invasive surgeries and the preference for minimally invasive procedures over other traditional procedures are the key market drivers fostering the growth of the market.

Source: Primary Research, MRFR Database, Secondary Research, and Analyst Review

Hemostasis and Tissue Sealing Agents Market Trends

• Growing preference for minimally invasive surgeries is driving the market growth

Market CAGR for hemostasis and tissue sealing agents is driven by the growing preference for minimally invasive surgeries. In recent years, there has been a noticeable change toward a preference for minimally invasive surgical techniques. Fewer postoperative complications, shorter hospital stays, smaller incisions, and faster recovery times are advantages of minimally invasive surgery. Systemic hemostatic medications, such as gelatin and collagen-based hemostat powders, are frequently used in minimally invasive procedures. These compounds enable surgeons to carry out complex surgeries. The results of a study by the World Health Organisation (WHO) indicate that around 234.2 million major surgical procedures are carried out worldwide annually in hospitals and other surgical facilities. The need for hemostats and tissue sealing agents consequently rises as the total number of surgical procedures rises and minimally invasive treatments become more popular.

The number of surgical procedures is predicted to climb as the prevalence of chronic illnesses rises globally. It is also anticipated that this will increase demand for wound healing and closure care. The CDC estimates that 150 million Americans have at least one chronic condition that requires surgery. Diabetes is one of the main causes of increased surgical operations, along with neurological, urological, and cardiac conditions. Diabetes and cardiovascular disorders are becoming more common in the Middle East, Africa, and Asia. Hemostats, adhesives, and tissue-sealing agents will increasingly be used as the number of accidents and procedures and the prevalence of chronic diseases increase.

The rise in senior populations worldwide has encouraged the quest for less intrusive surgical procedures. This demand is encouraging the market for hemostasis and tissue-sealing agents to grow. The numerous advantages of undergoing these surgical procedures can be blamed for the rising popularity of minimally invasive procedures. These benefits include fewer incisions, a quicker recovery period, less time spent in the hospital, and a lower chance of complications following surgery. Most often, systemic hemostasis agents based on collagen and gelatin are used in these specific surgical procedures. These medications are accessible globally as hemostasis and tissue-sealing agents. This element drives the demand for hemostasis and tissue-sealing agents in the market. Thus, driving the hemostasis and tissue sealing agents market revenue.

Hemostasis and Tissue Sealing Agents Market Segment Insights

Hemostasis and Tissue Sealing Agents Product Insights

The hemostasis and tissue-sealing agents market segmentation, based on product, includes topical hemostats and mechanical. Due to its use in conjunction with conventional treatment to provide cost-efficiency, quick & simple absorbability of the hemostatic agent, low tissue reactivity, and non-antigenicity, the topical hemostat sector accounted for the greatest part of the revenue in 2022.

July 2021:Baxter International Inc., a leading international medical products organization, disclosed the completion of the acquisition of certain assets related to CryoLife, Inc PerClot Polysaccharide Hemostatic System for $60.8 million, including a $25 million upfront payment, through its Baxter Healthcare Corporation subsidiary. Baxter enters the appealing hemostatic powder segment with PerClot while increasing our surgical solutions and complementing our recent acquisition of the Seprafilm Adhesion Barrier.

Additionally, in 2022, the mechanical sector witnessed the fastest growth rate. They work by attaching to and closing the injured tissues. Binding aids in promoting coagulation and forms a barrier over the wounds from surgery and injuries. Faster procedure times, low infiltration, fewer post-operative infections, and the prevention of other body fluid exudation are the causes driving their demand for sutures.

Hemostasis and Tissue Sealing Agents End-User Insights

The hemostasis and tissue-sealing agents market segmentation, based on end-user, includes hospital and ambulatory centers. The market was dominated by the hospital sector, accounting for 61.4% of market revenue (2.1 Billion). The main factor driving this sector’s domination is that hospitals in both developed and developing nations handle the majority of surgical procedures since they have the resources needed for such sophisticated surgical instruments and techniques. In addition, ambulatory centers experienced the fastest growth rate. The ambulatory center's treatment center segment is driven by increased military conflicts that call for combat activities.

Figure 1: Hemostasis and Tissue-Sealing Agents Market, by End-User, 2022 & 2032 (USD Billion)

Source: Primary Research, MRFR Database, Secondary Research, and Analyst Review

Hemostasis and Tissue Sealing Agents Regional Insights

By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American hemostasis and tissue sealing agents market area will control this market due to the high clinical research and development budgets of governments and public and private organizations, the presence of major manufacturers for the products, and the high volume of surgical procedures. The desire for less invasive surgical procedures has been fueled by the region's aging population, which also encourages growth in the market for hemostasis and tissue-sealing agents.

Further, the key countries studied in the market report are US, Canada, UK, German, Italy, France, Spain, India, China, Australia, Japan, South Korea, and Brazil.

Figure 2: HEMOSTASIS AND TISSUE SEALING AGENTS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Primary Research, MRFR Database, Secondary Research, and Analyst Review

Europe’s hemostasis and tissue sealing agents market accounts for the second-largest market share. The growing elderly population, which ultimately results in more surgeries, is anticipated to fuel the regional market. One of the primary drivers propelling market expansion in the area is a growing understanding of the usage of hemostatic agents, adhesives, and tissue sealants to lower the risk of postoperative bleeding. Further, the German hemostasis and tissue sealing agents market held the major market share, and the UK hemostasis and tissue sealing agents market was the rapidly growing market in the European region.

The Asia-Pacific Hemostasis and Tissue Sealing Agents Market is expected to grow at a rapid rate from 2023 to 2032. A rise in surgical operations and medical tourism brings this on. The main forces behind regional growth are liberal policies and an affordable environment. The top three nations having a huge patient base, a comparably more developed healthcare system, and cutting-edge therapies are India, China, and Japan. Moreover, China’s hemostasis and tissue sealing agents market held the major market share, and the Indian hemostasis and tissue sealing agents market was the rapidly growing market in the Asia-Pacific region.

Hemostasis and Tissue Sealing Agents Competitive Insights & Key Market Players

Leading market players are investing largely in research and development to expand their product lines, which will help the hemostasis and tissue sealing agents market, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, contractual agreements, mergers and acquisitions, collaboration with other organizations, and increased investments. If the hemostasis and tissue sealing agents industry is to expand and flourish in a demanding and increasingly competitive setting, it must offer reasonably priced solutions.

Local production to cut operating costs is one of the most crucial business methods employed by producers in the hemostasis and tissue sealing agents industry to help clients and broaden the market sector. In recent years, the hemostasis and tissue sealing agents industry has offered some of the most significant advantages to medicine. Major players in the hemostasis and tissue sealing agents market, including MIL Laboratories Pvt. Ltd, Cohera Medical, Inc., Integra Lifesciences Corporation, Baxter International, Inc, Johnson & Johnson, and others, are investing in research and development operations to improve market demand.

MedTrade is a wound care and consumer health product manufacturer based in the United Kingdom. The company provides gelling fiber, antimicrobials, superabsorbents, aerosols, and liquid skin protectors, assisting in addressing and resolving critical healthcare concerns such as biofilm, wound therapy, infection prevention, and bleeding control. In November 2022, MedTrade was a wound care and consumer health product manufacturer based in the United Kingdom. The company provides gelling fiber, antimicrobials, superabsorbents, aerosols, and liquid skin protectors, assisting in addressing and resolving critical healthcare concerns such as biofilm, wound therapy, infection prevention, and bleeding control.

Medcura is a wound care platform developer that may be utilized in various clinical and non-clinical settings to manage a wide range of high-impact surgical bleeds. The company's platform converts abundant natural resources into sophisticated wound care and hemostatic solutions for medical, military, and consumer uses. In July 2021, Medcura Inc., in collaboration with ASO LLC, a prominent US manufacturer and supplier of first aid items, announced the debut of Rapid-Seal, a high-performance, antibacterial hemostatic gel, at a large US pharmacy chain. The Food and Drug Administration (FDA) cleared wound gel from Medcura is the first in a new class of medicines with antibacterial capabilities to improve wound therapy, prevent wound infections, and create a safe healing environment.

Key Companies in the hemostasis and tissue sealing agents market include

• 
  

  Johnson & Johnson

  
  


• 
  

  Cryolife, Inc.

  
  


• 
  

  Baxter International, Inc

  
  


• 
  

  Ethicon LLC

  
  


• 
  

  Integra Lifesciences Corporation

  
  


• 
  

  Becton

  
  


• 
  

  Dickinson & Company

  
  


• 
  

  Cohera Medical, Inc.

  
  


• 
  

  Pfizer, Inc

  
  


• 
  

  Medtronic plc

  
  


• 
  

  Braun Melsungen AG

  
  


• 
  

  MIL Laboratories Pvt. Ltd

  
  


• 
  

  Advanced Medical Solutions Group Plc

  
  


• 
  

  Others

  
  

Hemostasis and Tissue Sealing Agents Industry Developments

May 2022:Ethicon, a division of Johnson & Johnson MedTech, has introduced the ENSEAL X1 Straight Jaw Tissue Sealer, a new advanced bipolar energy device that cuts and transects, enables stronger sealing, and catches more tissue per bite than Medtronic's LigaSure Blunt Tip tissue sealing device.

April 2022:Precision BioLogic Inc., a hemostasis diagnostic tool developer, has announced the availability of their new cryocheck Chromogenic Factor IX assay in Canada, the United Kingdom, the European Union, Australia, and New Zealand. CRYOcheck Chromogenic Factor IX is the only chromogenic FIX assay approved by Health Canada and one of only three CE-recognised assays. Its distinctive frozen packaging enables quick and easy preparation.

Hemostasis and Tissue Sealing Agents Market Segmentation

Hemostasis and Tissue Sealing Agents Product Outlook

• 
  

  Topical Hemostats

  
  


• 
  

  Mechanical

  
  

Hemostasis and Tissue Sealing Agents End-User Outlook

• 
  

  Hospital

  
  


• 
  

  Ambulatory Centers

  
  

Hemostasis and Tissue Sealing Agents Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America